A systematic review and meta-analysis revealed that a 2-fold increase in the standardized mean difference (SMD) of the IgA level occurred in advanced cancer compared with early carcinoma, further supporting the possibility that serum IgA levels may correlate with immune escape and tumor burden (48). This evidence concerns the gene CD79A and neoplasm.